Loki Therapeutics Announces Seed Financing To Develop Therapeutics That Enhance Longevity And Treat Immune-System Related Diseases

Company

About

Loki Therapeutics is developing next-generation therapeutics that leverage vaccination recall antigens to enhance longevity and treat immune-system related diseases, including cancer, by delivering vaccine recall antigens to tumor cells with genetically attenuated bacterial vectors. Loki's AWAKETM platform offers a completely new approach to treating cancer and other diseases caused by immune-system breakdown by activating and redirecting pre-existing memory T cells created during vaccination to target and eliminate cancer cells, as well as target other immune-related diseases. Key to AWAKE is its utilization of attenuated Listeria Monocytogenes for the precise delivery of recall antigens to tumor environments and into the tumor cell. Loki's lead development program – AWAKE-LM-TT – capitalizes on the childhood vaccination for tetanus toxoid (TT) to generate an immune response to solid tumors and metastases presenting the tetanus antigens. Loki is currently advancing AWAKE-LM-TT as a potential treatment for metastatic pancreatic cancer, as well as metastatic ovarian cancer. Loki is also pursuing additional development programs based on other childhood vaccines, including polio (AWAKE-LM-PV) and mumps. For more information on Loki Therapeutics please visit www.lokitx.com.